Loading clinical trials...
Loading clinical trials...
This is a study evaluating the utility of current Primary Ciliary Dyskinesia (PCD) diagnostic tests, including nasal nitric oxide testing.
This study is a prospective data collection of individuals referred to the investigators clinical center for considerations of PCD. Participants sign informed consent to have clinical information entered into a secure electronic database. As part of this study, participants may have nasal nitric oxide (nNO) testing performed. nNO testing is a research procedure, but it is a test with growing utility for making a diagnosis of PCD when performed in the right clinical setting.
Age
1 - No limit years
Sex
ALL
Healthy Volunteers
No
Vanderbilt Children's hospital
Nashville, Tennessee, United States
Start Date
June 1, 2017
Primary Completion Date
June 1, 2028
Completion Date
June 1, 2028
Last Updated
July 1, 2025
200
ESTIMATED participants
nNO testing
OTHER
Lead Sponsor
Vanderbilt University Medical Center
NCT07274631
NCT07417267
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions